Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis

Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis

Marc De Hert,1 Anna Eramo,2 Wally Landsberg,3 Dusan Kostic,4 Lan-Feng Tsai,5 Ross A Baker4 1Department of Neurosciences, KU Leuven, Belgium; 2Lundbeck LLC, Deerfield, IL, USA; 3Otsuka Pharmaceutical Europe Ltd., Wexham, UK; 4Otsuka Pharmaceutical Development & Commercialization, Inc., Princ...

Full description

Bibliographic Details
Main Authors:	De Hert M, Eramo A, Landsberg W, Kostic D, Tsai LF, Baker RA
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-05-01
Series:	Neuropsychiatric Disease and Treatment
Online Access:	http://www.dovepress.com/efficacy-and-safety-of-aripiprazole-once-monthly-in-obese-and-nonobese-peer-reviewed-article-NDT

Similar Items

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
by: Peters-Strickland T, et al.
Published: (2019-06-01)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
by: Wang SM, et al.
Published: (2014-08-01)

Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study.
by: Steven G Potkin, et al.
Published: (2017-01-01)

Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
by: Madera JJ, et al.
Published: (2019-06-01)

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
by: Daniel Schöttle, et al.
Published: (2018-11-01)

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia
by: Michele Wilson, et al.
Published: (2016-03-01)

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
by: Christophe Sapin, et al.
Published: (2016-09-01)

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
by: Daniel Schöttle, et al.
Published: (2018-12-01)

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
by: Oya K, et al.
Published: (2015-09-01)

The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia
by: Hidenobu Suzuki, et al.
Published: (2017-05-01)

Correction: Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study.
by: PLOS ONE Staff
Published: (2017-01-01)

Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
by: Madera J, et al.
Published: (2019-08-01)

Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study
by: Nestor Szerman, et al.
Published: (2020-02-01)

Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study
by: Nestor Szerman, et al.
Published: (2020-02-01)

Once-monthly paliperidone injection for the treatment of schizophrenia
by: Delia Bishara
Published: (2010-09-01)

Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
by: Joseph R. Calabrese, et al.
Published: (2018-06-01)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
by: Si T, et al.
Published: (2019-06-01)

The clinical utility of serum level of Aripiprazole and Dehydro-aripiprazole in schizophrenia
by: Hui-Hsin Chuang, et al.
Published: (2016)

The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study
by: Amatniek, J., et al.
Published: (2018)

Aripiprazole for late-life schizophrenia
by: Jeffrey Rado, et al.
Published: (2010-08-01)

Review of depot aripiprazole for schizophrenia
by: Motiwala FB, et al.
Published: (2013-11-01)

Role of aripiprazole in treatment-resistant schizophrenia
by: Mossaheb N, et al.
Published: (2012-05-01)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
by: O'Donnell A, et al.
Published: (2021-01-01)

Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients
by: Torres-Llenza V, et al.
Published: (2018-01-01)

Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations
by: Tchobaniouk LV, et al.
Published: (2020-02-01)

Aripiprazole – therapeutic efficacy and safety in everyday practice
by: Karina Nowakowska, et al.
Published: (2019-12-01)

Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole
by: Izchak Kohen, et al.
Published: (2010-03-01)

Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia.
by: Zhenhe Zhou, et al.
Published: (2013-01-01)

Aripiprazole-associated tic in a schizophrenia patient
by: Guo X, et al.
Published: (2015-03-01)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
by: Hodgson RE
Published: (2019-08-01)

Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation
by: Christoph U. Correll, et al.
Published: (2020-11-01)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting [Corrigendum]
by: Hodgson RE
Published: (2019-09-01)

Development and socialization of restrained eating in obese and nonobese youngsters
by: Isbitsky, Joyce
Published: (1987)

The influences of ethnicity on the eating styles of obese and nonobese individuals
by: Luera, Louis Dan, 1949-
Published: (1978)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
by: Li HF, et al.
Published: (2015-12-01)

Effect of aripiprazole and olanzapine on the cognitive function in patients with schizophrenia
by: Xiao-Hong Wang
Published: (2020-05-01)

Aripiprazole for refractory catatonic schizophrenia – A case report
by: Saisudha N V Gorthi, et al.
Published: (2015-01-01)

Treatment of refractory catatonic schizophrenia with low dose aripiprazole
by: Sasaki Tsuyoshi, et al.
Published: (2012-05-01)

Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
by: Li H, et al.
Published: (2018-04-01)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
by: Paula Rackoff
Published: (2009-05-01)